Disclosures. H. S. Sader, Allergan: Research Contractor, Research support, M. Castanheira, Allergan: Research Contractor, Research support, R. E. Mendes, Allergan: Research Contractor, Research support, R. K. Flamm, Allergan: Research Contractor, Research support.

1524. Are Providers Shifting from NTF to Fosfomycin for Inpatient UTI? Big Data Reveals Small Shifts

Kalpana Gupta, MPH1, Matthew B. Goetz, MD1, Makoto Jones, MD, MS1 and Judith M. Strymish, MD1; 1VA Healthcare System, West Roxbury, MA, Boston University School of Medicine, Boston, Massachusetts, 2David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, 3Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, 4Ideas Center, VA Salt Lake City Health Care System, Salt Lake City, Utah, 5Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah and 6VA Healthcare System, West Roxbury, MA, Harvard Medical School, Boston, Massachusetts

Session: 150. Urinary Tract Infection
Friday, October 5, 2018: 12:30 PM

Background. Fosfomycin (FOS) and NTF (NTF) are IDSA guideline approved drugs for acute cystitis in women. However, their activity against multi drug-resistant Gram-negatives may be driving increase used in inpatients with more complexly treated UTI. We evaluated trends in inpatient prescribing of these UTI-specific agents in the predominantly male population of the national VA system over a 7-year period.

Methods. All inpatient bar coded administrations for FOS and NTF at every VA facility nationwide from 2011 to 2017 were captured through a data analytics platform which extracts data from the VA Data Warehouse. Antibiotic days of therapy and rates per 1,000 patient-days (DOT/1,000CD) were extracted by year and compared using Mantel-Haenszel chi square for linear trend (MH OR). Demographics were captured via administrative data.

Results. Prescriptions from over 65 million patient-days spanning 7 years and all inpatient units in 129 VA facilities were included. Approximately 96% of patients were male with a mean age range of 55–64 years. FOS use increased from 128 prescriptions in 2011 to a high of 1,230 in 2016 and 1,003 in 2017 (figure). At the maximum in 2016, prescription rates increased almost 10-fold compared with 2011 (MH OR 9.8, P < 0.001). NTF prescriptions declined from 26,590 in 2011 to 19,343 in 2017. Rates decreased 22% from 2.8 to 2.1, MH OR 0.75, P < 0.001. In 2017, FOS and NTF usage rates were highest in rehabilitation/spinal cord units (table).

Conclusion. In this large nationwide cohort, FOS use increased almost 10-fold among predominantly male inpatients while NTF use declined slightly. NTF is still used for treatment of infections with more dangerous and multidrug-resistant bacteria. Both agents retain activity against many MDR GNRs but differences in efficacy, tissue penetration, familiarity and availability likely influence the choice for UTI-specific treatment.

| 2017 Data | ICU | MEDSURG | NH | PSYCH | REHAB/SCI |
|-----------|-----|----------|----|-------|-----------|
| FOS DOT/1,000CD | 0.06 | 0.15 | 0.07 | 0.03 | 0.73 |
| NTF DOT/1,000CD | 0.58 | 1.46 | 2.41 | 2.55 | 9.35 |
| FOS | 28 | 389 | 229 | 58 |
| NTF days | 251 | 3,099 | 7826 | 2,634 | 4,013 |

Disclosures. All authors: No reported disclosures.

1525. Evaluation of Clinical Outcomes With Fosfomycin for E. coli and Non-E. coli Enterobacteriaceae Urinary Tract Infections

Tiffany Lee, PharmD1; Lauren Glaser, MD, PhD1 and Kevin Alby, PhD1; 1Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 2Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Session: 150. Urinary Tract Infection
Friday, October 5, 2018: 12:30 PM

Background. Fosfomycin is a broad-spectrum oral antibiotic increasingly used for the treatment of uncomplicated and complicated urinary tract infections (UTIs). The Clinical and Laboratory Standards Institute (CLSI) does not support fosfomycin susceptibility testing on urinary isolates outside of Enterococcus faecalis and Escherichia coli. This is in light of building evidence and concern for the presence of chromosomal fosA gene in non-E. coli Enterobacteriaceae. Regardless, clinicians have continued to test and use fosfomycin for these pathogens due to multidrug resistance or intolerance to other agents without ample data on clinical implications.

Methods. This retrospective study included patients who received fosfomycin for the treatment of a UTI caused by any Enterobacteriaceae for which fosfomycin testing was performed from March 2016 through April 2018. We separated patients who received fosfomycin for the treatment of UTIs caused by E. coli from those caused by other Enterobacteriaceae for comparison. The primary outcome is the rate of clinical success at 48 hours, defined as the absence of UTI symptoms and normalization of vital signs. The secondary outcome is the rate of recurrent UTIs caused by the same pathogen within 30 days of the index infection.

Results. There were 28 separate episodes of E. coli UTIs in 24 patients and 25 separate episodes of non-E. coli UTIs in 26 patients included in this study. Patients were mostly balanced between the two groups and were on average about 64 years old, mostly females (61%), and had an average Charlson Comorbidity Index of 5. All E. coli isolates were susceptible to fosfomycin, while only 82.8% non-E. coli isolates were fosfomycin-susceptible. The rates of clinical success were similar between the E. coli and non-E. coli groups (89.3% vs. 88.5%). There was a higher rate of recurrence of the same UTI with E. coli (15.4%) than with non-E. coli (4.8%).

Conclusion. Findings from this small study suggest favorable outcomes with use of fosfomycin for non-E. coli Enterobacteriaceae. Despite recommendations against testing and use of fosfomycin in these pathogens, it appears that in vitro resistance does not always correlate with clinical response.

Disclosures. All authors: No reported disclosures.

1526. Oral Fosfomycin Use for Urinary Tract Infections and Its Clinical Impact on Hospital Stay

Christina Mai, MD1, Henry Donaghy, MD2 and Thien-Ly Doan, PharmD1; 1Internal Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, 2Medicine–Infectious Diseases, Long Island Jewish Medical Center, New Hyde Park, New York and 3Department of Pharmacy, Long Island Jewish Medical Center, New Hyde Park, New York

Session: 150. Urinary Tract Infection
Friday, October 5, 2018: 12:30 PM

Background. Oral fosfomycin is a treatment option for urinary tract infections (UTI) caused by multi-drug-resistant organisms (MDRO). The objective of the study was to describe the prescribing pattern of fosfomycin and determine its role in (1) preventing hospital admissions for patients seen in the emergency department or (2) promoting earlier discharges for admitted patients.

Methods. This retrospective chart review evaluated adults that received at least one dose of fosfomycin during the period 2014–2017. Information was collected using electronic medical records (e.g., demographics, symptoms, dose/duration of fosfomycin, urine culture results, length of stay, and hospital readmission). Statistical analysis was performed using descriptive statistics.

Results. Forty-three patients were included (60.5% females). Nearly half of the population (48.8%) had a history of recurrent UTIs. Patients received fosfomycin for cystitis (58.1%), pyelonephritis (34.9%), and asymptomatic bacteriuria (7%). Only two patients received >1 dose. Empiric use of fosfomycin was seen in only 9.3%. Of those treated based on culture results, 84.6% of patients had MDROs (2 ESBL, 2 VRE, 1 KPC, 1 resistant-Pseudomonas). No isolates had fosfomycin susceptibilities permitted. In 72% of the time, patients had no other oral options. In 74.3% of the time, fosfomycin was used as step-down therapy from intravenous (IV) antibiotics (e.g., carbapenems 69%, ceftazime 13.8%). Infectious Diseases was consulted on 81.4% of cases. Seven percent of patients had documented allergies to the preferred agent. Treatment success was seen in 93% of patients, while three patients failed treatment requiring readmission for IV therapy. Fosfomycin use resulted in earlier discharge in 75.8% of cases (range of 1–6 days, mean 2.92 hospital days avoided per patient). For those who received fosfomycin as part of their emergency visit, 90% (9 of 10) were able to avoid hospitalization.

Conclusion. In our study, fosfomycin was used in UTI caused by MDROs, with treatment success demonstrated in a majority of patients. Fosfomycin allowed for patients to avoid hospitalization or promoted earlier discharge, on average, 3 days sooner than anticipated. Use of fosfomycin should be considered in appropriate patients in an effort to decrease length-of-stay or altogether avoid hospitalization.

Disclosures. All authors: No reported disclosures.

1527. The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect of Clinical Outcomes

Michael Dunne, MD1; Vikas Gupta, PharmD, BCPS1; Steven Aronin, MD1 and Sailaja Puttagunta, MD2; 1Iberville Therapeutics, Old Saybrook, Connecticut, 2Becton, Dickinson and Company, Franklin Lakes, New Jersey

Session: 150. Urinary Tract Infection
Friday, October 5, 2018: 12:30 PM

Background. Over 99% of all outpatient urinary tract infections (UTI) in the United States are treated with either a quinolone, β-lactam, trimethoprim-sulfamethoxazole (T/S) or nitrofurantoin (NHF). Resistance to all classes of antibiotics is now seen in common uropathogens (e.g., E. coli, K. pneumoniae, P. aeruginosa). To our knowledge, this is the only study published in the United States that describes the prevalence of ENT resistant to all major classes of oral antibiotics and their effect on clinical outcomes.